New GranuFlo Lawsuit Website from Bernstein Liebhard LLP Provides Vital Dialysis Recall Information, Instructions on Filing a Claim
The Firm is eager to hear from any dialysis patient who may have suffered a stroke, heart attack, sudden cardiac death or another cardiovascular injury following treatment with Granuflo.
New York, NY (PRWEB) October 27, 2013
For individuals who may have experienced a stroke, heart attack, sudden cardiac death or another cardiovascular injury stemming from the now-recalled dialysis medication, a new GranuFlo lawsuit (http://www.granuflolawsuitclaims.com/) website from the attorneys at Bernstein Liebhard LLP is now available to answer any questions you have about filing a claim.
A growing number of dialysis patients have already filed lawsuits over the medication recalled in June 2012 alongside NaturaLyte, a fellow acid concentrate manufactured by Fresenius Medical Care. On its new website, the nationwide law firm will provide information about the side effects that have allegedly been associated with these dialysis drugs, which may include the risk for heart attacks, strokes, cardiopulmonary arrest, sudden cardiac death and other complications that may lead to dialysis death. NaturaLyte and GranuFlo side effects are allegedly experienced within 72 hours of receiving the drugs.
“As our Firm’s attorneys continue to hear from individuals who allegedly suffered the horrifying side effects of GranuFlo and NaturaLyte, our new website will prove vital to anyone seeking to file a claim against their manufacturer,” says Bernstein Liebhard LLP, a law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. Potential GranuFlo lawsuit claimants may also call the firm directly to receive free and confidential case evaluations.
According to an update issued October 17th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), a total of 612 lawsuits have now been filed in a federal NaturaLyte and GranuFlo litigation underway in the U.S. District Court, District of Massachusetts.* These cases similarly allege that Fresenius Medical Care, a leading supplier of dialysis products and services in the U.S., failed to adequately warn about the life-threatening cardiovascular side effects associated with its products prior to issuing an Urgent Product Notification on March 29, 2012.
Following this public health announcement, the U.S. Food and Drug Administration (FDA) issued a Class I recall of Granuflo and NaturaLyte in June 2012 after learning of the drugs’ potential to cause fatal heart injuries in dialysis patients. A New York Times report published that month indicated that the federal agency became aware of an internal memo sent by Fresenius in November 2011 that contained information about 900 dialysis deaths that occurred after GranuFlo and NaturaLyte dialysis treatments.**The notice was only sent to physicians operating in clinics owned and operated by Fresenius.
According to the Times, the FDA had launched an investigation into whether Fresenius violated federal law in its handling of the GranuFlo recall. According to the article, doctors outside the company’s network did not know GranuFlo and NaturaLyte contained more of an ingredient the body converts to bicarbonate than similar medications, and that the difference could mean a patient’s experiencing elevated bicarbonate levels in the bloodstream. In turn, this may result in metabolic alkalosis, a condition that can allegedly lead to fatal or near-fatal cardiovascular injuries.
In addition to lawsuits filed at the federal court level, court documents indicate that numerous GranuFlo-related claims are also currently pending in a state court proceeding underway in Middlesex County Superior Court in Massachusetts. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)
Dialysis patients and their families may be entitled to compensation for injuries allegedly sustained within 72 hours of a dialysis treatment that used GranuFlo or NaturaLyte. Learn more about last year’s recall when you contact a GranuFlo lawyer or by visiting Bernstein Liebhard LLP’s website. For additional information, and to arrange for a free case review, please call 800-511-5092.
*jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf; U.S. Judicial Panel on Multidistrict Litigation, October 17, 2013
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11271730.htm